A $10B settlement? Or $45B? Distributors, AGs go back and forth in opioid talks: Bloomberg

Distributors have pitched a $10 billion opioid settlement with state attorneys general, Bloomberg reports. (SARINYAPINNGAM/iStock/Getty Images Plus)

In the complex tangle of opioid lawsuits against drugmakers and distributors, one big number has emerged, Bloomberg reports

The nation’s top three drug distributors—McKesson, AmerisourceBergen and Cardinal Health—have verbally offered a $10 billion settlement with state attorneys general, according to the news service. AGs hit back with a much higher demand of $45 billion. Bloomberg cited three unnamed people familiar with the discussions in its reporting.

A McKesson representative told Bloomberg “we regularly engage with the state attorneys general, but the company has made no settlement offers.” The other companies declined to comment, the news service reports.  


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Drugmakers and distributors face thousands of lawsuits alleging pharma companies oversold the benefits and downplayed the risks of using opioids to treat chronic pain. Plaintiffs say distributors failed to monitor suspicious orders and flooded communities with millions of pills. Together, the conduct contributed to a national opioid epidemic, the plaintiffs say. Aside from thousands of lawsuits from cities and counties, state attorneys general are conducting their own probes and lawsuits.  

Importantly, the offer was reportedly made in negotiations with state attorneys general. It isn’t clear whether cities and counties would join a potential deal struck by AGs, or whether they'd pursue their own damages.

RELATED: Ditch the opioid 'negotiating class' proposal, experts say. State attorneys general are better suited to reach a deal 

Investors sent shares for the distributors down by about 6% Tuesday afternoon. 

Aside from talks with AGs, plaintiffs in the lawsuits brought by cities and counties have proposed a novel “negotiating class” to help the sides reach a deal, but one expert told FiercePharma that idea isn’t helping. Perry Zinn Rowthorn, formerly a Connecticut deputy attorney general and now a partner at Shipman & Goodwin, argued that AGs are better suited to reach a deal. Then localities could join in, he said.

A federal judge in Cleveland signaled support for the “negotiating class” idea on Tuesday, Legal Newsline reports. The first trial in the multidistrict litigation is set for October, but defendants have asked for a delay, citing the complexity of the litigation. 

Analysts have put forth a range of estimates into potential liabilities for drugmakers and distributors, with Wells Fargo's David Maris saying the issue could cost defendants up to $100 billion.

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…